Hanna Artemchuk1, Tiina Eriksson2, Mario Poljak3, Heljä-Marja Surcel4,5, Joakim Dillner1,6, Matti Lehtinen1,2, Helena Faust1. 1. Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. 2. University of Tampere, Finland. 3. Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Slovenia. 4. Faculty of Medicine, University of Oulu, Oulu, Finland. 5. European Science Infrastructure Services, Oulu, Finland. 6. Clinical Pathology/Cytology, Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden.
Abstract
Background: Most cervical cancers are caused by vaccine-preventable infections with human papillomaviruses (HPV). The HPV prophylactic vaccines Gardasil and Cervarix have been widely used for >10 years and are reported to induce high antibody levels. A head-to-head comparison of the antibody responses induced by the 2 vaccines has been performed only up to 5 years. Methods: Among 3300 Finnish females aged 16-17 years who got 1 of the 2 HPV vaccines in phase 3 licensure trials, virtually all consented to registry-based long-term follow-up. Linkage with the Finnish Maternity Cohort found that they donated >2500 serum samples up to 12 years later. Sera of 337 (38.6%) Gardasil and 730 (30.3%) Cervarix vaccine recipients were retrieved from the Finnish Maternity Cohort biobank and type-specific anti-HPV antibody levels were determined using in-house multiplexed heparin-HPV pseudovirion Luminex assay. Results: Anti-HPV-16 and anti-HPV-18 antibody levels remained stable and above natural infection-related antibody levels for up to 12 years for most vaccine recipients. The median antibody levels were higher among Cervarix recipients 7-12 years post vaccination (P < .0001). Conclusions: The stability of vaccine-induced antibody levels is in accordance with the high long-term protection reported previously. The differences in antibody levels induced by the 2 vaccines imply that continued follow-up to identify possible breakthrough cases and estimation of the minimal protective levels of serum antibodies is a research priority.
Background: Most cervical cancers are caused by vaccine-preventable infections with human papillomaviruses (HPV). The HPV prophylactic vaccines Gardasil and Cervarix have been widely used for >10 years and are reported to induce high antibody levels. A head-to-head comparison of the antibody responses induced by the 2 vaccines has been performed only up to 5 years. Methods: Among 3300 Finnish females aged 16-17 years who got 1 of the 2 HPV vaccines in phase 3 licensure trials, virtually all consented to registry-based long-term follow-up. Linkage with the Finnish Maternity Cohort found that they donated >2500 serum samples up to 12 years later. Sera of 337 (38.6%) Gardasil and 730 (30.3%) Cervarix vaccine recipients were retrieved from the Finnish Maternity Cohort biobank and type-specific anti-HPV antibody levels were determined using in-house multiplexed heparin-HPV pseudovirion Luminex assay. Results: Anti-HPV-16 and anti-HPV-18 antibody levels remained stable and above natural infection-related antibody levels for up to 12 years for most vaccine recipients. The median antibody levels were higher among Cervarix recipients 7-12 years post vaccination (P < .0001). Conclusions: The stability of vaccine-induced antibody levels is in accordance with the high long-term protection reported previously. The differences in antibody levels induced by the 2 vaccines imply that continued follow-up to identify possible breakthrough cases and estimation of the minimal protective levels of serum antibodies is a research priority.
Authors: Simopekka Vänskä; Tapio Luostarinen; Iacopo Baussano; Dan Apter; Tiina Eriksson; Kari Natunen; Pekka Nieminen; Jorma Paavonen; Ville N Pimenoff; Eero Pukkala; Anna Söderlund-Strand; Gary Dubin; Geoff Garnett; Joakim Dillner; Matti Lehtinen Journal: J Infect Dis Date: 2020-08-17 Impact factor: 5.226
Authors: Juan Carlos Sierra-Rojas; Ramón Reyes-Carreto; Cruz Vargas-De-León; Jorge Fernando Camacho Journal: Comput Math Methods Med Date: 2022-08-23 Impact factor: 2.809
Authors: Ana Paula Costa; Paulo César Giraldo; Ricardo Ney Cobucci; Márcia Lopes Consolaro; Raquel Pantarotto Souza; Luanda Barbara Canário; Paula Renata Machado; Rand Randall Martins; Pedro Vieira Baptista; José Eleutério Jr; Ana Katherine Gonçalves Journal: Asian Pac J Cancer Prev Date: 2020-09-01
Authors: J Hoes; H Pasmans; T M Schurink-van 't Klooster; F R M van der Klis; R Donken; J Berkhof; H E de Melker Journal: Hum Vaccin Immunother Date: 2021-05-25 Impact factor: 3.452